Prosecution Insights
Last updated: April 19, 2026
Application No. 17/996,310

HERBICIDAL COMPOUNDS

Non-Final OA §101§102§112
Filed
Oct 14, 2022
Examiner
KUCHARCZK, JED A
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Syngenta Crop Protection AG
OA Round
1 (Non-Final)
80%
Grant Probability
Favorable
1-2
OA Rounds
2y 7m
To Grant
99%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allow Rate
68 granted / 85 resolved
+20.0% vs TC avg
Strong +21% interview lift
Without
With
+20.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
32 currently pending
Career history
117
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
31.6%
-8.4% vs TC avg
§102
17.0%
-23.0% vs TC avg
§112
27.1%
-12.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 85 resolved cases

Office Action

§101 §102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The information disclosure statements (IDS) submitted on 10/14/2022 and 12/05/2023 were filed in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner. Claim Objections Claims 1 and 5 objected to because of the following informalities: Claim 1 recites “wherein:-“ which should recite “wherein:[-]”. Claim 5 recites “-SO2methyl” which should recite “-SO2[m]methyl”. Appropriate correction is required. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claim 15 is rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. Claim 15 does not fall within at least one of the four categories of patent eligible subject matter because claim 15 recites “use of a compound of Formula (I) as defined in claim 1 as a herbicide.” Because claim 1 is drawn to a use per se, it does not fall within at least one of the four categories of patent eligible subject matter. For example, a “use of a compound. . . as a herbicide” does not define a proper process because it lacks active steps. See MPEP 2173.05(q). Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 15 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 15 is indefinite because it recites the “use of a compound of Formula (I) as defined in claim 1 as a herbicide” without setting forth any active steps defining how the use is practiced, leaving the metes and bounds of the claim unclear. See MPEP 2173.05(q). Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim 16 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS RN 873980-66-6 (12/05/2023 NPL Cite No 12). CAS RN 873980-66-6 PNG media_image1.png 128 164 media_image1.png Greyscale anticipates a compound of Formula (V) wherein R2 is halogen wherein the halogen is Br, R3 is C1alkyl, R4 is C1alkyl and R5 is hydrogen. Claim 17 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS RN 194360-83-3 (12/05/2023 NPL Cite No 16). CAS RN 194360-83-3 PNG media_image2.png 147 279 media_image2.png Greyscale anticipates a compound of Formula (VI) wherein R2 is -S(O)pC1alkyl wherein p is 0, R3 is C1alky-l, R4 is C5alkyl- and R3 is hydrogen. Allowable Subject Matter Claims 1-14 and 18 are allowable over the prior art. Conclusion Claims 15-17 are rejected. Claims 1 and 5 are objected to. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JED A KUCHARCZK whose telephone number is (571)270-5206. The examiner can normally be reached Mon-Fri 7:30 to 5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan can be reached at (571) 270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JED A KUCHARCZK/Examiner, Art Unit 1623 /ADAM C MILLIGAN/Supervisory Patent Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Oct 14, 2022
Application Filed
Feb 23, 2026
Non-Final Rejection — §101, §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600710
BETA-CATENIN AND B-CELL LYMPHOMA 9 (BCL9) INHIBITORS
2y 5m to grant Granted Apr 14, 2026
Patent 12599617
METHODS OF TREATING HEAD AND NECK CANCERS WITH HEMP EXTRACT
2y 5m to grant Granted Apr 14, 2026
Patent 12595253
BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12577260
BIPHENYL COMPOUND AS IMMUNOMODULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
2y 5m to grant Granted Mar 17, 2026
Patent 12570645
USES OF P53 X-RAY CO-CRYSTAL STRUCTURES
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
80%
Grant Probability
99%
With Interview (+20.9%)
2y 7m
Median Time to Grant
Low
PTA Risk
Based on 85 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month